Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies-Reference-Cited by-同舟云学术

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

Published:2024-03-24 Issue:7 Volume:13 Page:1873
ISSN:2077-0383
Container-title:Journal of Clinical Medicine
language:en
Short-container-title:JCM

Author:

Tommasi Chiara¹²³^ORCID,Airò Giulia¹²³^ORCID,Pratticò Fabiana¹²³,Testi Irene¹²,Corianò Matilde¹²³,Pellegrino Benedetta¹³,Denaro Nerina⁴^ORCID,Demurtas Laura⁵,Dessì Mariele⁵,Murgia Sara⁶,Mura Giovanni⁷,Wekking Demi⁸^ORCID,Scartozzi Mario⁵⁶^ORCID,Musolino Antonino¹²³^ORCID,Solinas Cinzia⁵

Affiliation:

1. Medical Oncology and Breast Unit, University Hospital of Parma, 43126 Parma, Italy

2. Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy

3. GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), 43100 Parma, Italy

4. Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy

5. Medical Oncology, AOU Cagliari, Policlinico Duilio Casula, 09042 Monserrato, Italy

6. Medical Oncology, University of Cagliari, 09124 Cagliari, Italy

7. Pathological Anatomy, Laboratory Valdès, 81200 Cagliari, Italy

8. Academic Medical Centre, Amsterdam University Medical Center, University of Amsterdam, 1098 XH Amsterdam, The Netherlands

Abstract

Hormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care options both in neoadjuvant/adjuvant settings and in advanced disease. Additionally, we focus on new trials and drugs for HR-positive/HER2-positive breast cancer and the new entity: HER2-low breast cancer.

Publisher

MDPI AG

Link

https://www.mdpi.com/2077-0383/13/7/1873/pdf

Reference132 articles.

1. Multitargeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer;Nahleh;Am. J. Clin. Oncol.,2005

2. (2023, June 18). Female Breast Cancer Subtypes—Cancer Stat Facts, Available online: https://seer.cancer.gov/statfacts/html/breast-subtypes.html.

3. HER2-Low Breast Cancer: Pathological and Clinical Landscape;Tarantino;J. Clin. Oncol.,2020

4. Therapeutic Implications of Estrogen Receptor Signaling in HER2-Positive Breast Cancers;Nahta;Breast Cancer Res. Treat.,2012

5. Optimizing Treatment for HER2-Positive HR-Positive Breast Cancer;Debien;Cancer Treat. Rev.,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology;Regulatory Mechanisms in Biosystems;2024-05-11